A retail trade report maps out the points where grocers can connect with shoppers taking GLP-1 drugs.
Recap by typeshit. Full story at Progressive Grocer.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
The multi-year trial, Oura's first, will test whether ring data on sleep, heart rate and activity lines up with weight loss, HbA1c and staying on treatment.
A retrospective matched study of 16,792 type 2 diabetes patients linked prior GLP-1 drug use to lower mortality from necrotizing soft tissue infection.
Loading…